Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

M. A. Socinski, R. M. Jotte, F. Cappuzzo, F. Orlandi, D. Stroyakovskiy, N. Nogami, D. Rodriguez-Abreu, D. Moro-Sibilot, C. A. Thomas, F. Barlesi, G. Finley, C. Kelsch, A. Lee, S. Coleman, Y. Deng, Y. Shen, M. Kowanetz, A. Lopez-Chavez, A. Sandler, M. Reck*IMpower150 Study Grp, Anne-Marie Dingemans

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)2288-2301
Number of pages14
JournalNew England Journal of Medicine
Volume378
Issue number24
DOIs
Publication statusPublished - 14 Jun 2018

Keywords

  • PHASE-III TRIAL
  • OPEN-LABEL
  • CANCER
  • BEVACIZUMAB
  • THERAPY
  • DOCETAXEL
  • ANTIBODY
  • CELLS
  • CHEMOTHERAPY
  • MULTICENTER

Cite this